Ranbaxy SA Pty, a wholly owned subsidiary of Ranbaxy Laboratories, has opened its new manufacturing facility, Be-Tabs Pharmaceuticals Manufacturing Plant, at Roodepoort, Johannesburg, South Africa.
This will be the company's second manufacturing facility in South Africa and the third in the African continent.
The new facility, built with an investment of $30 million will manufacture analgesics, cold, cough and flu preparations, anti-histamines, anti-hypertensives, central nervous system drugs, vitamins and minerals as well as a comprehensive range of over-the-counter medication. The products manufactured will comprise tablets and hard gelatin capsules.
Ranbaxy said the plant is capable of producing approximately 1.75 billion units and packaging of two billion units, annually.
"Ranbaxy has a long standing relationship with Africa. We were the first Indian pharmaceutical company to set up a manufacturing facility in Nigeria, in the late 70's. Over the years, we have established a strong presence in 43 of the 54 African countries with the aim of providing quality medicines and improving access. The opening of this new manufacturing facility further emphasizes our commitment towards the African continent and South Africa in particular," said Arun Sawhney, managing director of Ranbaxy.
